Vyjuvek™ (beremagene geperpavec-svdt) – New orphan drug approval
May 19, 2023 - The FDA announced the approval of Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt), for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Top